

5 June 2018



(Stock code : 0690)

Uni-Bio Science and Beijing Baiao Pharmaceutical entered into strategic cooperation agreement on the development of oral antidiabetic drugs, Acarbose tablets

[5 June 2018 – Hong Kong] A leading integrated biopharmaceutical researcher, developer and manufacturer – **Uni-Bio Science Group Limited** (“**Uni-Bio Science**” or “**the Group**”; stock code: 0690) is pleased to announce that after the trading hours of The Stock Exchange of Hong Kong Limited on 5 June 2018, Beijing Genetech Pharmaceutical Co., Limited (a wholly-owned subsidiary of the Company) and Beijing Baiao Pharmaceutical Co., Ltd. (“**Beijing Baiao Pharmaceutical**”) entered into a strategic cooperation agreement on the joint development and promotional marketing of Acarbose tablets project. Beijing Baiao Pharmaceutical will, pursuant to the said agreement, invest to acquire interests in Acarbose tablets products and be entitled to future marketing revenue. The relevant expenses on project research shall be borne by both parties. Meanwhile, as a marketing authorization holder, the Group shall be responsible for the management of pre-launch declaration and registration and the arrangement of post-launch production and sales, while Beijing Baiao Pharmaceutical shall be responsible for the post-launch promotion of the products in the markets of designated provinces. The signing ceremony was held this morning at Beijing Genetech Pharmaceutical Co., Ltd.



This cooperation is the first launched project in the multiple drug co-development agreement announced and entered into between the Group and Beijing Sun-Novo Pharmaceutical Research Co., Limited on 1 December 2016 (for details, please refer to the announcement in the Appendix). Acarbose tablet is an oral anti-diabetic drug. It is used to treat Type 2 diabetes and is reimbursed under the National Reimbursement Drug List. It targets patients with pre-diabetes condition who need to be treated early, and those with post prandial hyperglycemia under control. According to the data provided by Menet, the terminal market for Acarbose in public medical institutions in China was RMB6.25 billion in 2016, increased by 6.95% year-on-year, representing its huge significance in the China market. At present, Acarbose tablet has limited competitors in China and the main manufacturers are Bayer, Huadong Pharmaceutical Co.,Ltd and Luye Pharma Group, forming a tripartite situation. Currently, the Group has completed the testing processes on production technique of Acarbose tablets and related bioequivalence study will be initiated shortly. The Group has a leading research progress and expecting to be the first batch of manufacturers to apply for production approvals in the research projects. It had already completed the process preparation review in 2017 and is expecting the application for new drug registration to be submitted in the first half of 2019.

Beijing Baiao Pharmaceutical was established on 19 January, 1995 by the Chinese Academy of Sciences with a registered capital of RMB55 million. It is located in Changping Park, a national independent innovation demonstration area in Zhongguancun, Beijing. It is one of the famous and representing enterprises of “Bioengineering and New Medicine Segment” of Changping Garden. Beijing Baiao Pharmaceutical is committed to technological innovation and industrialization, specializing in the production of therapeutic proteins and peptides such as Lumbru kinase. Through successful reorganization, Beijing Baiao Pharmaceutical has now become one of the key companies in bio-pharmaceutical and chemical drug production under the Sino Cavir Bio-Pharmaceutical Science and Technology Co.,Ltd, the same shareholder as Beijing Sun-Novo Pharmaceutical Research Co., Limited.

Addressing this cooperation, **Mr. Kingsley Leung**, Chairman of and Executive Director of Uni-Bio Science Group Limited commented, “This cooperation will attain synergy by fully consolidating the Group’s experience in the research and development of metabolizers and the achievements Baiao Pharmaceutical has made in the biopharmaceutical field. Through this cooperation, we will speed up the development and marketing of oral anti-diabetic drugs to capture the huge domestic market opportunities. In the future, Uni-Bio Science will strive to continue upholding the slogan of “Leading genuine innovation” and spirit “International execution to achieve win-win”, and endeavoring to provide Chinese people with safe and highly effective drug treatment solutions.

– End –

About Uni-Bio Science Group Limited



Uni-Bio Science Group Limited is principally engaged in the research and development, manufacture and distribution of pharmaceutical products. The research and development center located in Dongguan, PRC is fully equipped with a complete system for the development of genetically-engineered products with a pilot plant test base which is in line with CFDA requirements. The Group also has two GMP manufacturing bases in Beijing and Shenzhen. The Group is focused on the development of novel treatments addressing the therapeutic areas of diabetes, ophthalmology and dermatology.

Uni-Bio Science Group Limited was listed on the Main Board of the Hong Kong Stock Exchange on November 12, 2001. Stock code: 0690.

This press release is issued by DLK Advisory Limited for and on behalf of **Uni-Bio Science Group Limited**.

For further information, please contact:



DLK Advisory

Michelle Shi (michelleshi@dlkadvisory.com)

Linda Liang (lindaliang@dlkadvisory.com)

Cathy Wu (cathywu@dlkadvisory.com)

Max Lau (maxlau@dlkadvisory.com)

Tel: +852 2857 7101

Fax: +852 2857 7103

WeChat ID: Unibio-IR

心 創 造 新 醫 藥
LEADING GENUINE INNOVATION

促進增長 國際視野 Accelerating Growth International Execution

